Clinical trials: DNA Damage
Infertility
DNA Damage and Subfertility in Males - Impact on ART Outcome
A obvational prospective cohort study of men undergoing IUI, IVF and ICSI treatment in Denmark. The aim is to asses the impact of sperm DNA damage, measured as DNA fragmentation index (DFI), on reproductive outcomes after…
- Trial name
- ReproDNA (NCT04160208)
- Where
- Denmark
- Volunteers
- 1,350 people
- Sponsor
- Regionshospitalet Viborg, Skive
Metastatic Triple Negative Breast Cancer
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib [AZD6738]) and…
- Trial name
- NCT03330847
- Testing
- Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle)., Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
- Where
- 141 sites in United States, Belgium and 13 more
- Volunteers
- 273 people
- Sponsor
- AstraZeneca
Colorectal Cancer
Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA
Single Centre, open label assignment phase II clinical study. To evaluate the effect of oral 200mg Methylene Blue tablets (administered 8x25mg) prior to endoscopy on double stranded DNA breaks in colonic biopsy samples assessed…
- Trial name
- NCT02295774
- Testing
- Methylene Blue MMX tablets
- Where
- Italy
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Cosmo Technologies Ltd
Head and Neck Squamous Cell Carcinoma
A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC).
This biomarker study has been designed to assess the effects of different agents in both tumour tissue and peripheral samples to help inform the best combinations of DDR agents with immuno-oncology (IO) therapies.
- Trial name
- NCT03022409
- Testing
- Ceralasertib, Olaparib
- Where
- 4 sites in United States, France and 1 more
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Advanced Solid Tumours
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
- Trial name
- NCT04564027
- Testing
- Ceralasertib
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Febrile Seizures, Oxidative Stress
8-OHdG and Oxidative Stress in Febrile Seizures
This prospective case-control study investigates whether serum 8-hydroxy-2'-deoxyguanosine (8-OHdG), an established biomarker of reactive oxygen species-mediated DNA oxidation, is elevated in children with febrile seizures…
- Conditions
- Febrile Seizures, Oxidative Stress, Oxidative DNA Damage
- Trial name
- NCT07660003
- Testing
- Group 1 Health Controls, Group 2 SFC, Group 3 CFC
- Where
- Turkey (Türkiye)
- Volunteers
- 156 people
- Sponsor
- Kayseri City Hospital
Ultraviolet Rays; Injury, DNA Adduct Formation
Quantification of DNA Repair Products in the Urine After Ultraviolet Radiation of the Skin
Purpose of the experiment The investigators know that DNA damage is formed in the skin by sun exposure of the thymine-dimer type. Many of these injuries are repaired and excreted through the urine.
- Conditions
- Ultraviolet Rays; Injury, DNA Adduct Formation, DNA Damage, Radiation Induced, DNA Damage
- Trial name
- NCT05277961
- Testing
- Ultraviolet radiation
- Where
- Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Bispebjerg Hospital
Polycystic Ovary Syndrome, Chronic Periodontitis
Chronic Periodontitis and Polycystic Ovary Syndrome
Background: The aim of this study was to investigate the levels of malondialdehyde (MDA), total antioxidant status (TAS), 8-hydroxy-2´- deoxyguanosine (8-OHdG) in blood serum and saliva samples in female patients with chronic…
- Trial name
- NCT02954120
- Testing
- no intervention provided
- Where
- Turkey (Türkiye)
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Chronic HCV-related Hepatitis
Coffee Effect in HCV-related Hepatitis
Background: In patients with chronic HCV-related liver damage, coffee is associated with a reduced risk of progression and of hepatocellular carcinoma (HCC) development.
- Trial name
- NCT01572103
- Testing
- Coffee, coffee abstinence
- Volunteers
- 40 people
- Sponsor
- Azienda Ospedaliera di Padova
Smoking
Feasibility and Smokers' Reactions to DNA Feedback
The purpose of the study is to explore how feedback of cellular DNA (Deoxyribonucleic Acid) damage, as a marker of exposure to the genotoxic agents of tobacco smoke, promotes cessation.
- Trial name
- NCT02922790
- Testing
- standard health information, standard health information plus info. on DNA damage, Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Duke University
Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor CB-839 with the poly adenosine diphosphate ribose…
- Conditions
- Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer
- Trial name
- NCT03875313
- Testing
- CB-839, Talazoparib
- Where
- 9 sites in United States
- Volunteers
- 33 people
- Sponsor
- Calithera Biosciences, Inc
Advanced Solid Tumors
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary clinical activity of M9466 in combinations with carboplatin in advanced or metastatic refractory solid tumor…
- Trial name
- NCT06719973
- Testing
- M9466, Carboplatin, Etoposide
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Low-Level Light Therapy, Renal Insufficiency, Chronic
Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure
This study aims to verify the effects of low level laser therapy (LLLT) on functional capacity, DNA damage, lower limbs muscle strength, quadriceps muscle architecture, muscle pain and perception of lower limb fatigue…
- Conditions
- Low-Level Light Therapy, Renal Insufficiency, Chronic, Renal Dialysis, Clinical Trial
- Trial name
- NCT03250715
- Testing
- Low Level Laser Therapy
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Federal University of Health Science of Porto Alegre
Pulmonary Arterial Hypertension
Olaparib for PAH: a Pilot Study
The main OBJECTIVE of this proposal is to extend our preclinical findings on the role of DNA damage and poly(ADP-ribose) polymerases (PARP) inhibition as a therapy for a devastating disease, pulmonary arterial hypertension (PAH)…
- Trial name
- OPTION-p (NCT03251872)
- Testing
- Olaparib
- Where
- Canada
- Volunteers
- 6 people
- Sponsor
- Laval University
HBOC Syndrome, DNA Damage
Nutritional Intervention and DNA Damage of Patients With HBOC
Breast and Ovarian Cancer Syndrome (HBOC) is characterized by mutations in tumor suppressor genes such as BRCA1 and BRCA2, which increase the carrier's risk of developing breast and ovarian cancer, especially before 40.
- Conditions
- HBOC Syndrome, DNA Damage, Nutrition Therapy
- Trial name
- NCT05306002
- Testing
- Antioxidant therapy
- Where
- Mexico
- Volunteers
- 34 people
- Sponsor
- Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado
Non Small Cell Lung Cancer
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in…
- Trial name
- CONCORDE (NCT04550104)
- Testing
- Radiotherapy, Olaparib Oral Tablet [Lynparza], AZD1390
- Where
- 14 sites in United Kingdom
- Volunteers
- 200 people
- Sponsor
- University of Leeds
Healthy Volunteers
Cutaneous DNA Damage Caused by UV-A Irradiation
The DIMUVA study aims to evaluate the correlation between cutaneous phototype and the nature and quantity of damage caused to cutaneous DNA after exposure to UV-A radiation.
- Trial name
- DIMUVA (NCT00864955)
- Testing
- UVA and UVB irradiation
- Where
- 2 sites in France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Healthy Volunteers, Age Group: 60-70
Effect of an Anti-ageing Supplement on Oxidative Stress
This pilot study serves to investigate whether ProManna intake leads to any changes in baseline levels for oxidative stress markers.
- Conditions
- Healthy Volunteers, Age Group: 60-70, Overweight
- Trial name
- PromAge (NCT03272867)
- Testing
- ProManna
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Recurrent Glioma, Recurrent Glioblastoma
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma.
- Conditions
- Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation
- Trial name
- TAC-GReD (NCT04740190)
- Testing
- Talazoparib
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong